For patients with symptomatic sickness necessitating therapy, ibrutinib is often proposed based on 4 period III randomized clinical trials evaluating ibrutinib with chlorambucil monotherapy106 and also other typically utilized CIT combinations, specifically FCR, bendamustine plus rituximab and chlorambucil additionally obinutuzumab (ClbO).107–109